Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
In this webinar, a detailed discussion is done on Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Speakers : Dr. Sushant Mittal - Moderator ,Dr. Randeep Singh - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Davinder Paul - Panelist
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
Early management of CNS metastases in ALK-positive NSCLC using next-gen ALK inhibitors improves intracranial control and patient outcomes.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
Explore innovative strategies for early CNS disease detection, integrating neuroimaging, biomarkers, and clinical assessment to enhance diagnostic precision and outcomes.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
Explore Lorlatinib’s role in first-line ALK+ mNSCLC treatment, highlighting key findings from the CROWN trial.`
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
In this webinar, a detailed discussion is done on Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
Explore treatment sequencing strategies for ALK+ NSCLC patients with CNS diseases, focusing on targeted therapies and CNS-penetrant treatments.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
Explore unmet needs in ALK-positive NSCLC, including resistance, CNS metastases, biomarker-driven therapies, and advances in precision oncology.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
Explore key findings from the CROWN trial for ALK+ NSCLC patients with CNS metastases and treatment advances.
Speakers : Dr. Sushant Mittal - Moderator ,Dr. Randeep Singh - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Davinder Paul - Panelist
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Patients face high out-of-pocket costs after incident cancer diagnosis
2.
In a study, immune detection of oral cancers is linked to obesity.
3.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
4.
Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.
5.
Common intracellular toxin could help fight leukemia
1.
Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options
2.
The Latest Research on Chronic Granulomatous Disease and Promising New Treatments
3.
Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources
4.
Florinef: Understanding Its Uses and Side Effects
5.
Uncovering the Subtle Signs of Leukemia: A Guide to Early Detection
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
2.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
3.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge